ClinicalTrials.Veeva

Menu

Registry of X-linked Adrenoleukodystrophy

Capital Medical University logo

Capital Medical University

Status

Enrolling

Conditions

X-linked Adrenoleukodystrophy

Study type

Observational

Funder types

Other

Identifiers

NCT05939232
KY2023-011-02

Details and patient eligibility

About

This study is a observational study conducted through recruiting X-linked adrenoleukodystrophy (X-ALD) patients, to build a comprehensive evaluation and long-term follow-up platform for X-ALD patients, and to provide a theoretical basis for the treatment and management of X-ALD patients.

Full description

In this study, X-ALD patients will be selected as study participants. Through a longitudinal collection of genetic, imaging and clinical symptoms data of the patients and carriers. The purpose of this study is to build a comprehensive evaluation and long-term follow-up platform for X-ALD patients. Through the long-term follow-up of imaging and clinical symptoms progress and outcome of X-ALD patients, combined with genetic data, we will improve the relationships between genes and phenotypes, and explore the deep insight in the pathophysiological mechanism of X-ALD, to provide a theoretical basis for the treatment and management of X-ALD patients.

Enrollment

200 estimated patients

Sex

All

Ages

6 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

X-ALD group:

  • Meet the diagnostic criteria of X-ALD and supported by the results of genetic and very long chain fatty acid (VLCFA) test;
  • Age: 6 - 70 years old;
  • Able to communicate normally, and complete the test of scale as instructed (confirmed by the field test of scale);
  • Sign the informed consent.

Carrier-control group:

Healthy people who have no significant difference in age, sex and education comparing with the X-ALD group, volunteer to participate in this study, could complete the test of scale as instructed, and meet the following criteria:

  • Eligible for asymptomatic carriers in genetic tests (preference of patient's mother and close relatives);
  • Age: 6 - 70 years old, able to complete the test of scale as instructed (confirmed by the field test of scale);
  • No history of psychiatric diseases.

Exclusion criteria

  • Other hereditary diseases;
  • Other severe central nervous diseases;
  • History of surgery of brain or eye;
  • Psychiatric and psychological diseases, such as anxiety and depression;
  • Metal foreign body or prosthesis in the human body (such as pacemaker and insulin pump), claustrophobia, and other MRI contraindications;
  • History of surgery associated with gastrointestinal tract;
  • No informed consent;
  • Unable to tolerate MRI or eye related tests.

Trial design

200 participants in 2 patient groups

X-ALD
Description:
X-linked adrenoleukodystrophy (X-ALD) patients.
Carrier-control (CC)
Description:
Carriers of mutation in gene encoding ATP-binding cassette subfamily D member 1 (ABCD1), who have no X-linked adrenoleukodystrophy and are matched with the X-ALD group according to age, sex and education.

Trial contacts and locations

1

Loading...

Central trial contact

Yilong Wang, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems